Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery
NCT ID: NCT06575049
Last Updated: 2024-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
60 participants
OBSERVATIONAL
2025-05-01
2026-02-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Analysis of Breast-Conserving Surgery Plus Whole-Breast Irradiation Versus Mastectomy
NCT05126667
Investigating the Use of Drains and (Internal) Quilting Sutures on Seroma Formation Following Mastectomy
NCT02668263
Quilting Sutures After Mastectomy
NCT06415032
Effect of Perioperative Intravenous Lidocaine Infusion and Magnesium Infusion on the Functional Recovery After General Anesthesia in the Patients Undergoing Breast Mastectomy
NCT02185859
Hypercoagulability After Breast Cancer Surgery
NCT00210197
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MAXIGESIC
Maxigesig group
No interventions assigned to this group
Ketololac
ketololac group
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with adequate renal function: serum Cr 1.4 mg/dL or less
* Patients with adequate liver function Bilirubin, AST/ALT: 1.5 times or less of the upper limit of normal, Alkaline phosphatase: 1.8 times or less of the upper limit of normal
* Patients undergoing total mastectomy with SLNB or ALND (mastectomy and axillary sentinel lymph node dissection)
* Patients undergoing breast-conserving surgery with ALND (mastectomy and axillary dissection)
* Patients who voluntarily decided to participate in this study and signed a written informed consent form
Exclusion Criteria
* Patients with drug allergies to painkillers and anti-inflammatory drugs
* Patients with a physical condition that would interfere with understanding and submitting the consent form
20 Years
70 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hyeong-Gon Moon
PF.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2312-168-1498
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.